Xcytrin motexafin gadolinium: Phase II data

In a Phase II trial in 60 evaluable patients with recurrent NSCLC, Xcytrin monotherapy produced 3 partial responses and 17 cases of stable disease. Median survival was 9.2 months, and the 1-year survi...